Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

Recent Milestones
edit

Omthera Pharmaceuticals received $33.9M in Series B funding. (3/14/11)

Posted 3/14/11 at 9:32pm via fiercebiotech.com
Omthera Pharmaceuticals received $6.5M in Series A funding. (3/30/10)

Posted 3/29/10 at 10:57pm via onbiovc.com
Omthera Pharmaceuticals added Jerry Wisler as President & CEO, Board Member, Co-Founder.

Posted 3/15/11 at 3:59am
Omthera Pharmaceuticals added David Mott as Board of Directors.

Posted 3/14/11 at 9:37pm
Omthera Pharmaceuticals added Michael H. Davidson as Chief Medical Officer, Co-Founder.

Posted 3/15/11 at 3:59am
Omthera Pharmaceuticals added Christian S. Schade as Executive Vice President and CFO.

Posted 8/4/11 at 6:04pm